Brief: Oncolytics Biotech Partner Adlai Nortye Advances Chinese Bridging Trial Of Pelareorep-Paclitaxel Combination Treatment In Breast Cancer To Final Dosing Cohort
24/03/2022 11:09
March 24 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® PARTNER ADLAI NORTYE ADVANCES CHINESE
BRIDGING TRIAL OF PELAREOREP-PACLITAXEL COMBINATION TREATMENT IN
BREAST CANCER TO FINAL DOSING COHORT
* ONCOLYTICS - FIRST TWO COHORTS INDICATE PELAREOREP IN
COMBINATION WITH PACLITAXEL WAS WELL-TOLERATED WITH NO NEW
SAFETY SIGNALS OBSERVED TO DATE
* ONCOLYTICS BIOTECH - FINAL COHORT'S DOSING REGIMEN IS
EQUIVALENT
TO ONCOLYTICS' NORTH AMERICAN PHASE 2 TRIAL IN METASTATIC BREAST
CANCER (BRACELET-1)
* ONCOLYTICS - TRIAL DESIGNED TO SATISFY REGULATORY NEEDS,
ACCELERATE PELAREOREP'S DEVELOPMENT IN CHINA, HONG KONG, MACAU,
TAIWAN, SINGAPORE, S. KOREA
Source text for Eikon: ID:nPn7HvC5ha
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer